Physician profile
Esther Mannix
NPI 1477106102
$2,898.60
in general payments reported to CMS, 2019-2025
24 companies · $438 in 2025
The $438 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $20.39 · 2021: $99.33 · 2022: $680 · 2023: $601 · 2024: $784 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,822.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $288.33 | 2023-2025 | Hydrus Microstent, Tryptyr, Rocklatan |
| Abbvie INC. | $250.90 | 2023-2024 | |
| Bausch & Lomb Americas INC. | $241.57 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Allergan, INC. | $229.39 | 2021-2022 | |
| Sight Sciences, INC. | $229.27 | 2024-2025 | Tearcare System, Omni Surgical System |
| Oyster Point Pharma, INC. | $179.23 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Glaukos Corporation | $151.01 | 2019 | |
| Horizon Therapeutics Plc | $146.76 | 2022-2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $124.99 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $124.08 | 2022 | |
| Biotissue Holdings INC. | $122.07 | 2022 | |
| New World Medical,INC. | $108.72 | 2024 | Clearpath, Streamline, Kahook Dual Blade |
| Ani Pharmaceuticals, INC. | $96.86 | 2024 | Purified Cortrophin Gel |
| Tarsus Pharmaceuticals, INC. | $88.32 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $86.14 | 2022-2023 | Acthar |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $79.29 | 2023-2024 | Eylea, Eylea Hd |
| Dompe US, INC. | $72.86 | 2024 | Oxervate |
| Novartis Pharmaceuticals Corporation | $69.72 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $68.33 | 2024-2025 | |
| Harrow Eye, LLC | $57.12 | 2024-2025 | Vevye, Verkazia, Natacyn |
| Genentech USA, INC. | $23.75 | 2023 | Vabysmo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.39 | 2020 | |
| Astellas Pharma US INC | $20.24 | 2025 | Izervay |
| Thea Pharma INC. | $19.26 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esther Mannix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.